Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 56854Q200 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Suvretta Capital Management, LLC
13G
|
5.5% |
2/11/2025
Event 2/7/2025
|
||
| Suvretta Capital Management, LLC | 5.5% | |||
| Averill Master Fund, Ltd. | 5.5% | |||
| Aaron Cowen | 5.5% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (7) | ||||
| Vanguard Group Inc 13G/A | 4.7% |
1/31/2025
Event 12/31/2024
|
||
|
Tang Capital Partners LP
13G/A
|
3.0% |
2/14/2025
Event 12/31/2024
|
||
| Tang Capital Management, LLC | 3.0% | |||
| Kevin Tang | 3.0% | |||
| Tang Capital Partners, LP | 2.4% | |||
| Tang Capital Partners III, Inc | 0.6% | |||
| Tang Capital Partners IV, Inc | 0% | |||
|
Beryl Capital Management LLC
13G/A
|
0% |
5/15/2025
Event 3/31/2025
|
||
| Beryl Capital Management LLC | 0% | |||
| Beryl Capital Management LP | 0% | |||
| Beryl Capital Partners II LP | 0% | |||
| David A. Witkin | 0% | |||
|
Franklin Resources, Inc.
13G/A
|
0% |
2/11/2025
Event 12/31/2024
|
||
| Franklin Resources, Inc. | 0% | |||
| Charles B. Johnson | 0% | |||
| Rupert H. Johnson, Jr. | 0% | |||
|
Morgan Stanley
13G/A
|
0% |
3/6/2025
Event 2/28/2025
|
||
| Morgan Stanley | 0% | |||
| Morgan Stanley & Co. LLC | 0% | |||
|
Panacea Innovation Ltd
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Panacea Venture Healthcare Fund II, L.P. | 0% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 0% | |||
| Panacea Innovation Limited | 0% | |||
| James Huang | 0% | |||
|
Sofinnova Investments, Inc.
13G/A
|
0% |
2/12/2025
Event 12/31/2024
|
||
| Sofinnova Investments, Inc. | 0% | |||
| Sofinnova BioEquities GP LLC | 0% | |||
| James Healy | 0% | |||
| Eric Delbridge | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2024 Q4 | 57 | 29.6 M | $15.8 M |
| 2024 Q3 | 84 | 41.5 M | $73.8 M |
| 2024 Q2 | 98 | 43.5 M | $50.9 M |
| 2024 Q1 | 139 | 54.7 M | $494 M |
| 2023 Q4 | 126 | 54.5 M | $593 M |
| 2023 Q3 | 122 | 51.1 M | $411 M |
| 2023 Q2 | 121 | 44.7 M | $485 M |
| 2023 Q1 | 100 | 41.1 M | $284 M |
| 2022 Q4 | 87 | 40.6 M | $166 M |
| 2022 Q3 | 79 | 28.9 M | $187 M |
| 2022 Q2 | 79 | 28.8 M | $141 M |
| 2022 Q1 | 97 | 30.0 M | $281 M |
| 2021 Q4 | 86 | 30.0 M | $357 M |
| 2021 Q3 | 91 | 31.8 M | $362 M |
| 2021 Q2 | 91 | 31.5 M | $563 M |
| 2021 Q1 | 98 | 31.9 M | $493 M |
| 2020 Q4 | 101 | 29.8 M | $363 M |
| 2020 Q3 | 85 | 18.6 M | $239 M |